WNV E-DIII Specific Neutra™ Antibody Products

Are you struggling with the cross-reactivity of flavivirus antibodies or the low potency of candidates during early-stage development? Our WNV E-DIII specific Neutra™ antibody products help you overcome specificity challenges and accelerate lead validation through our advanced high-throughput B-cell screening and structural design platform. We deliver highly characterized, non-cross-reactive antibodies that ensure reliable downstream results for your diagnostic and therapeutic projects.

West Nile Virus (WNV) and the Biological Significance of E-DIII

Fig.1 Structure of WNV envelope protein and Domain III.¹

West Nile virus (WNV), a neurotropic flavivirus transmitted primarily by Culex mosquitoes, poses a significant global health threat. While the viral Envelope (E) protein mediates host cell entry, its Domain III (E-DIII) is the critical determinant of potent, type-specific immunity. Unlike Domain II, which is buried in the mature virion and often elicits broadly cross-reactive but weakly neutralizing antibodies, E-DIII is surface-exposed and immunodominant for potent neutralizing responses. In convalescent patients and animal models, antibodies targeting E-DIII correlate strongly with protection, making it the highest-priority target for developing specific therapeutic countermeasures and distinguishing WNV infections from serologically related flaviviruses.

• Key Antigenic Structure

The WNV E protein exists as a homodimer on the virion surface, with domain III (E-DIII) adopting an immunoglobulin-like β-sandwich fold stabilized by a conserved disulfide bridge. This domain harbors the lateral ridge (LR) epitope, a structurally conserved neutralizing determinant formed by three discontinuous loops (BC, DE, and FG). Landmark structural studies have shown that potent monoclonal antibodies (mAbs) target this lateral ridge, burying a large surface area (～800 Ų) and locking the E protein in its prefusion conformation. Critically, sequence variations in the surface-exposed residues of these loops distinguish West Nile virus from Dengue virus (DENV) and Zika virus (ZIKV), providing the structural basis for the high specificity of E-DIII–targeted reagents.

• Mechanism of Neutralization

Anti-WNV E-DIII antibodies function primarily by sterically occluding the receptor-binding site or blocking the massive conformational rearrangements required for viral fusion. Upon endocytosis, the acidic environment of the endosome typically triggers the E protein trimerization necessary for fusion with the endosomal membrane. High-affinity E-DIII antibodies bridge the viral surface domains, essentially "stapling" the E proteins in their pre-fusion dimer state. This blockade prevents the exposure of the hydrophobic fusion loop, thereby arresting the infection cycle before the viral genome can enter the cytoplasm. This mechanism is highly efficient; occupancy of only a fraction of the available epitopes (~30%) is often sufficient to render the virion non-infectious.

Fig. 2 The mechanism of anti-WNV E-DIII antibody neutralizing the virus.

• Disease and Diagnostic Relevance

WNV infection ranges from asymptomatic febrile illness to severe neuroinvasive disease (meningitis, encephalitis, acute flaccid paralysis), particularly in the elderly and immunocompromised. Accurate diagnosis is clinically vital but historically difficult due to extensive serological cross-reactivity among flaviviruses (e.g., St. Louis encephalitis, Zika). Antibodies specific to WNV E-DIII are essential diagnostic tools because they lack cross-reactivity with the highly conserved fusion loop epitope found in other flaviviruses. Consequently, anti-E-DIII mAbs enable the development of highly specific serological assays that can differentiate active WNV infection from prior vaccination or infection with related flaviviruses, reducing false positives in endemic regions.

Applications of Anti-WNV E-DIII Neutralizing Antibodies

Our catalog of highly characterized antibodies supports diverse critical applications in virology research:

• Next-Generation Diagnostics: High-affinity monoclonal antibodies (mAbs) targeting the lateral ridge of envelope domain III (E-DIII), a region of exceptional antigenic specificity, serve as indispensable capture or detection reagents in both antigen-capture ELISAs and rapid lateral flow assays. Their exquisite selectivity enables clear discrimination between West Nile virus (WNV) and closely related flaviviruses, such as Japanese encephalitis virus (JEV) and St. Louis encephalitis virus (SLEV), thereby minimizing cross-reactivity and enhancing diagnostic confidence in complex outbreak scenarios, where accurate patient stratification is paramount.
• Therapeutic Development: Humanized anti-E-DIII mAbs have shown remarkable promise in preclinical studies: when administered even after viral exposure, they significantly curb viremia, limit neuroinvasion, and improve survival in lethal murine challenge models. Beyond direct neutralization, some candidates engage Fc-mediated effector functions that amplify viral clearance. As such, they not only represent potential clinical therapeutics but also serve as gold-standard benchmarks for assessing the potency, breadth, and mechanism of action of next-generation antiviral biologics targeting neuroinvasive disease.
• Prophylaxis Research: For individuals at elevated risk, such as the elderly, transplant recipients, or those living in WNV-endemic regions, these mAbs are being explored as short-term prophylactic countermeasures. Current investigations delve into their pharmacokinetic profiles, tissue distribution, and capacity to neutralize virus in peripheral reservoirs before it breaches the blood-brain barrier. Optimizing half-life through Fc engineering further enhances their utility in bridging protection gaps where vaccines may be contraindicated or unavailable.
• Vaccine & Epitope Mapping: These well-defined mAbs are pivotal tools for dissecting immune responses at the molecular level. In competitive binding assays, they enable researchers to evaluate whether vaccine-induced antibodies target conformationally intact, protective E-DIII epitopes, or merely elicit non-neutralizing, cross-reactive responses against conserved but non-protective domains. This functional "immune fingerprinting" helps establish correlates of protection, guiding the rational design of safer, more effective subunit or mRNA-based vaccines that focus immunity on vulnerable sites of the viral envelope.

Our Anti-WNV E-DIII Neutra™ Antibody Products

Creative Biolabs offers a premium portfolio of recombinant antibodies engineered for consistency and performance. Every product in the Neutra™ line undergoes rigorous validation:

• Recombinant Precision: Monoclonal antibodies produced in mammalian expression systems with defined sequences and isotypes (IgG1, IgG4, etc.) to ensure batch-to-batch reproducibility.
• Functional Validation: Verified for biological activity using Plaque Reduction Neutralization Tests (PRNT) and Focus Reduction Neutralization Tests (FRNT) to guarantee potent viral inhibition.
• Structural Characterization: Epitope-mapped to ensure binding to the critical lateral ridge or receptor-binding motifs, confirming their utility for specific applications.
• Versatile Utility: Validated for use in ELISA, Western Blot, Immunofluorescence (IF), and in vivo protection studies, providing a comprehensive toolkit for your research needs.

Ready to advance your flavivirus research with reagents you can trust? Contact our team for more information and to discuss your project. Our scientists are available to assist with product selection, custom formulation, or bulk order inquiries to support your specific experimental requirements.

Reference

1. Austin, S. Kyle, and Kimberly A. Dowd. "B cell response and mechanisms of antibody protection to West Nile virus." Viruses 6.3 (2014): 1015-1036. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.3390/v6031015